Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Singapore
  4. Singapore Stock Exchange
  5. The Trendlines Group Ltd.
  6. News
  7. Summary
    42T   IL0011328858

THE TRENDLINES GROUP LTD.

(42T)
  Report
Delayed Singapore Stock Exchange  -  01:38 2022-12-01 am EST
0.0880 SGD   -6.38%
11/17Saturas Ltd. announced that it expects to receive $0.7 million in funding from Agriline Ltd., The Trendlines Group Ltd.
CI
11/17Escala Medical announced that it has received $0.672 million in funding from Agriline Ltd., The Trendlines Group Ltd.
CI
11/17Limaca Medical Ltd announced that it expects to receive $0.35 million in funding from The Trendlines Group Ltd., Agriline Ltd.
CI
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Vensica Therapeutics closes $16 million investment round

11/01/2021 | 05:27am EST

Vensica Therapeutic's innovative ultrasound-assisted delivery catheter for needle-free use in urological procedures.

Portfolio company, Vensica Therapeutics, a clinical stage biopharmaceutical company, announced that it has closed an investment round of $16 million. The investment round was led by Israel Biotech Fund ("IBF"), a venture fund investing in Israeli and Israeli-related biotechnology and pharmaceutical companies. Other investors in the round include Laborie, a global urology device company, Lew Pell, an experienced medical device investor, Agriline, a trust of which Vincent Tchenguiz is a discretionary beneficiary, and The Trendlines Group, an investor in innovation-based medical and agricultural technologies. The funds raised will support the company's phase II multicenter clinical trials in Europe and the USA.

The investment round follows an announcement by Vensica earlier this year on the signing of a strategic license and collaboration agreement with Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins. Vensica licensed Merz's botulinum neurotoxin A (XEOMIN®) for needle-free use in urological procedures. Vensica will expand its workforce in Israel for the next stage of clinical and regulatory development of its device together with XEOMIN®, focusing on overactive bladder treatment.

Vensica's needle-free platform for drug delivery will be utilized for botulinum toxin type A delivery into the urinary bladder for the treatment of different urological indications including overactive bladder, neurogenic bladder, and interstitial cystitis. Today's gold standard treatment requires needle injections of the neurotoxin into the bladder wall. Vensica's needle-free platform is expected to enable a far superior patient experience, to resolve many needle-associated issues, including pain, urinary retention, and to make a generally more complicated procedure easier. Vensica's platform is also anticipated to facilitate a more efficacious treatment through a more uniform delivery of the neurotoxin to the bladder wall.

Vensica CEO Avner Geva, commented,

Closing this investment round is an exceptional step for Vensica. Together with our partner and shareholder, Merz Therapeutics, and with the necessary funding, we are poised to plan and complete clinical and regulatory processes that will enable us to bring innovative and less invasive treatment of bladder diseases to the market.

Vensica Chair, Nissim Darvish, M.D., Ph.D., added,

it is our pleasure to welcome and thank our new investors, IBF and Agriline, joining our longstanding supporters Laborie, Lew Pell and The Trendlines Group. Vensica's team will work hard to get this solution to patients worldwide suffering from overactive bladder as well as other urinary bladder indications.

IBF's Co-Founder and Managing Partner, Ido Zairi, commented,

IBF is happy to join Vensica in this journey which may be life changing for many people suffering from bladder related conditions or diseases. We look forward to seeing Vensica's unique needle-free platform embedded as a method of treatment for overactive bladder and other indications.

Disclaimer

Trendlines Group Ltd. published this content on 01 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 November 2021 10:26:00 UTC.


ę Publicnow 2021
All news about THE TRENDLINES GROUP LTD.
11/17Saturas Ltd. announced that it expects to receive $0.7 million in funding from Agriline..
CI
11/17Escala Medical announced that it has received $0.672 million in funding from Agriline L..
CI
11/17Limaca Medical Ltd announced that it expects to receive $0.35 million in funding from T..
CI
11/07Celleste Bio announced that it has received funding from The Trendlines Group Ltd., Mon..
CI
10/21Singapore Stocks End Week with Losses; Soilbuild Construction Shares Soar 23% on Secur..
MT
10/21Trendlines Group Places Over 21 Million Shares to Four Investors; Shares Drop 3%
MT
09/14GreenSpense Ltd. announced that it expects to receive $0.4 million in funding from The ..
CI
09/14Sol-Chip Ltd. announced that it expects to receive $0.25 million in funding from Agrili..
CI
08/11The Trendlines Group Ltd. Appoints Low Teck Seng as an Independent and Non-Executive Di..
CI
08/11Transcript : The Trendlines Group Ltd., H1 2022 Earnings Call, Aug 11, 2022
CI
More news
Financials (USD)
Sales 2021 16,1 M - -
Net income 2021 6,56 M - -
Net cash 2021 8,45 M - -
P/E ratio 2021 12,8x
Yield 2021 -
Capitalization 60,1 M 60,1 M -
EV / Sales 2020 -17,4x
EV / Sales 2021 3,33x
Nbr of Employees 53
Free-Float 19,3%
Chart THE TRENDLINES GROUP LTD.
Duration : Period :
The Trendlines Group Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THE TRENDLINES GROUP LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
D. Todd Dollinger Co-Chairman & Co-Chief Executive Officer
Steve Rhodes Co-Chairman & Co-Chief Executive Officer
Haim Brosh CFO, Joint Secretary & Compliance Officer
Shahar Harari Chief Technology Officer
Irit Shemesh Catz Operations Director
Sector and Competitors
1st jan.Capi. (M$)
THE TRENDLINES GROUP LTD.-16.98%60
BLACKROCK, INC.-21.12%107 540
BROOKFIELD ASSET MANAGEMENT INC.-16.98%73 747
BLACKSTONE INC.-34.28%64 234
UBS GROUP AG4.90%57 700
KKR & CO. INC.-30.31%44 709